HALO vs. BIIB, UTHR, NBIX, INCY, BMRN, EXAS, RGEN, EXEL, MDGL, and IONS
Should you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry.
Halozyme Therapeutics vs.
Biogen (NASDAQ:BIIB) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends, profitability and community ranking.
Halozyme Therapeutics has a net margin of 41.43% compared to Biogen's net margin of 16.81%. Halozyme Therapeutics' return on equity of 179.82% beat Biogen's return on equity.
In the previous week, Biogen had 45 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 55 mentions for Biogen and 10 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.31 beat Biogen's score of 0.32 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.
Biogen has higher revenue and earnings than Halozyme Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.
Biogen presently has a consensus target price of $228.80, suggesting a potential upside of 58.97%. Halozyme Therapeutics has a consensus target price of $60.89, suggesting a potential upside of 7.50%. Given Biogen's higher probable upside, equities analysts clearly believe Biogen is more favorable than Halozyme Therapeutics.
87.9% of Biogen shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 0.2% of Biogen shares are owned by insiders. Comparatively, 2.4% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Biogen received 1286 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. Likewise, 71.71% of users gave Biogen an outperform vote while only 69.40% of users gave Halozyme Therapeutics an outperform vote.
Biogen has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.
Summary
Halozyme Therapeutics beats Biogen on 10 of the 18 factors compared between the two stocks.
Get Halozyme Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Halozyme Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:HALO) was last updated on 2/1/2025 by MarketBeat.com Staff
